Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 906-627-4 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
As the substance is a reaction mass consisting of Cyclohexanol and Cyclohexanone, data for both substances have been taken into accout.
No data on the actual reaction mass is available.
Cyclohexanone:
A guinea pig maximization test with pure Cyclohexanone showed negative results (Bruze et al.). A mouse ear swelling test, a guinea pig maximization test and a Buehler test (Gad et al., 1986) showed no skin sensitizing properties for Cyclohexanone.
Cyclohexanol:
In a dermal sensitisation GLP-compliant study according to OECD Guideline 406 with guinea pigs the test substance was not sensitising.
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- Principles of method if other than guideline:
- Magnusson B. and Kligman A .M., 1969. The identification of contact allergens by animal assay. The guinea pig maximization test. J. Invest. Dermatol. 52: 268-276.
- GLP compliance:
- yes
- Type of study:
- guinea pig maximisation test
- Justification for non-LLNA method:
- Guinea pig assay was available
- Species:
- guinea pig
- Strain:
- other: Pirbright White, Dunkin Hartley HOE DHPK [SPF-LAC] BO
- Sex:
- female
- Details on test animals and environmental conditions:
- - Source: Versuchstierzucht, Hagemann GmbH & Co . KG, D-4923 Extertal 1, FRG
- Rational for choice of animals: Because of the high sensitivity of guinea pigs to a sensitization of the skin which is supposed to be most like that of man. This animal species is the test object acknowledged worldwide for sensitization studies
- Weight at study initiation: 288-340g
- Randomization: According to Salfi, R. : A Long Peri-od Random Number Generator with Application to Permutation. Compstat 1974, pp. 28 - 35.
- Housing: 5/cage
- Diet: 341 .4 mm-Kaninchen- Meerschweinchen-Haltungsdiaet; ad libitum (Supplier : Firma Klingentalmühle AG , CH-4303 Kaiseraugst, Switzerland)
- Water: ad libitum (tap water; about 2 g of ascorbic acid per 10l water was added to the drinking water twice a week
Quality of water and feed used was ascertained via analysis
- Acclimation: no data
- Clipping of the test animals: if required, about 3 to 5 hours before each reading and before each test substance application at the appropriate application sites
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24°C
- Humidity (%): 30-70%
- Photoperiod (hrs dark / hrs light): 12/12 - Route:
- intradermal and epicutaneous
- Vehicle:
- olive oil
- Concentration / amount:
- Induction; Intradermal: 5%
Induction; topical: 50%
Challenge: 25%
Rechallenge:25% - Route:
- epicutaneous, occlusive
- Vehicle:
- olive oil
- Concentration / amount:
- Induction; Intradermal: 5%
Induction; topical: 50%
Challenge: 25%
Rechallenge:25% - No. of animals per dose:
- Control I: 10
Control II: 10
Test group: 20 - Details on study design:
- PRETEST TESTS: (performed 4 wks before main study)
Epidermal Application
- No. of animals: 4/concentration
- Site of application: flanks, respectively on the same areas
- Route of exposure: epicuteneous, patches of filter paper (2 x 2 cm) saturated with the test substance
- Type of coverage: occlusive
- Frequency/Duration: 2X for 24h within a period of 96h
- Evaluation (hr after patch removal): 24h and 48h, scoring of findings using Draize score system for scoring skin irritation
- Result: The minimum irritant concentration was found with a 50% test substance preparation in olive oil DAB 9 and the maximum non-irritant concentration with 25% test substance preparation in olive oil DAB 9 (48 h after the beginning of application).
MAIN STUDY
A. INDUCTION EXPOSURE
Intradermal Injection:
- Site: shoulder
- Concentration: 5% (0.1 ml/site)
- Vehicle: olive oil DAB 9
- Test group 1: Freund's complete adjuvant (FCA) 1:1 with physiological saline(0.9%).
- Test group 2: The test article in olive oil DAB 9.
- Test group 3: Freund's complete adjuvant 1:1 with physiological saline (0.9%) containing the test article
- Control group 1: Freund's complete adjuvant (FCA) 1:1 with physiological saline(0.9%).
- Control group 2: Olive oil DAB 9.
- Control group 3: Freund's complete adjuvant 1:1 with physiological saline (0.9%)
- Frequency of applications: 1x
- Evaluation (hr after injection): 24h, scoring of findings using Draize score system for scoring skin irritation
Topical Induction Exposure:
- Time Schedule: about 1 week after intradermal injections
- Site: same as intradermal injection
- Concentration: 50% cyclohexanol in Olive oil DAB 9 (test groups), olive oil DAB 9 (control groups)
- Route of exposure: epicuteneous, patches of filter paper (2 x 4 cm) saturated with the test substance
- Type of coverage: occlusive
- Duration: 48h.
- Evaluation (hr after injection): 48h, scoring of findings using Draize score system for scoring skin irritation
B. CHALLENGE EXPOSURE
1st Challenge: Test groups and control group 1 treated identically in the following manner
- Day(s) of challenge: 2 weeks after topical induction exposure
- Route of exposure: epicutaneous, applied to a 2 x 2cm piece of filter paper
- Exposure period: 24 h
- Site: intact clipped flank, right flank (test substance, 25% in vehicle), left flank (vehicle). Left flank of each control group 2 animal was treated with the vehicle. Right flank was not treated
- Vehicle: olive oil DAB 9
- Evaluation (hr after challenge): 24h, 48h and 72h, scoring of findings using Draize score system for scoring skin irritation
2nd Challenge- Test groups, control groups 1 and 2 treated identically in the following manner
- Start of challenge: 7days after 1st challenge
- Route of exposure: epicutaneous, applied to a 2 x 2cm piece of filter paper
- Exposure period: 24 h
- Site: intact clipped flank, right flank (vehicle), left flank (test substance; 25% in vehicle)
- Vehicle: olive oil DAB 9
- Evaluation (hr after challenge): 24h, 48h and 72h, scoring of findings using Draize score system for scoring skin irritation - Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 25% in olive oil DAB 9
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- slight erythema: 5/10 animals. no other findings
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: negative control. Dose level: 25% in olive oil DAB 9. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: slight erythema: 5/10 animals. no other findings.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- 25% in olive oil DAB 9
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- no symptom
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: negative control. Dose level: 25% in olive oil DAB 9. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: no symptom.
- Reading:
- other: 3rd reading
- Hours after challenge:
- 72
- Group:
- negative control
- Dose level:
- 25% in olive oil DAB 9
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- no symptom
- Remarks on result:
- other: Reading: other: 3rd reading. . Hours after challenge: 72.0. Group: negative control. Dose level: 25% in olive oil DAB 9. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: no symptom.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 25% in olive oil DAB 9
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- slight erythema: 12/20 animals. no other findings
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: test group. Dose level: 25% in olive oil DAB 9. No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: slight erythema: 12/20 animals. no other findings.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 25% in olive oil DAB 9
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- no symptom
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: test group. Dose level: 25% in olive oil DAB 9. No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: no symptom.
- Reading:
- other: 3rd reading
- Hours after challenge:
- 72
- Group:
- test chemical
- Dose level:
- 25% in olive oil DAB 9
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- no symptom
- Remarks on result:
- other: Reading: other: 3rd reading. . Hours after challenge: 72.0. Group: test group. Dose level: 25% in olive oil DAB 9. No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: no symptom.
- Reading:
- rechallenge
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 25% in olive oil DAB 9
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- slight to moderate erythema: 14/20. no other findings
- Remarks on result:
- other: Reading: rechallenge. . Hours after challenge: 24.0. Group: negative control. Dose level: 25% in olive oil DAB 9. No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: slight to moderate erythema: 14/20. no other findings.
- Reading:
- rechallenge
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- 25% in olive oil DAB 9
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- no symptom
- Remarks on result:
- other: Reading: rechallenge. . Hours after challenge: 48.0. Group: negative control. Dose level: 25% in olive oil DAB 9. No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: no symptom.
- Reading:
- rechallenge
- Hours after challenge:
- 72
- Group:
- negative control
- Dose level:
- 25% in olive oil DAB 9
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- no symptom
- Remarks on result:
- other: Reading: rechallenge. . Hours after challenge: 72.0. Group: negative control. Dose level: 25% in olive oil DAB 9. No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: no symptom.
- Reading:
- rechallenge
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 25% in olive oil DAB 9
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- slight to moderate erythema: 14/20. no other findings
- Remarks on result:
- other: Reading: rechallenge. . Hours after challenge: 24.0. Group: test group. Dose level: 25% in olive oil DAB 9. No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: slight to moderate erythema: 14/20. no other findings.
- Reading:
- rechallenge
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 25% in olive oil DAB 9
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- no symptom
- Remarks on result:
- other: Reading: rechallenge. . Hours after challenge: 48.0. Group: test group. Dose level: 25% in olive oil DAB 9. No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: no symptom.
- Reading:
- rechallenge
- Hours after challenge:
- 72
- Group:
- test chemical
- Dose level:
- 25% in olive oil DAB 9
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- no symptom
- Remarks on result:
- other: Reading: rechallenge. . Hours after challenge: 72.0. Group: test group. Dose level: 25% in olive oil DAB 9. No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: no symptom.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
Cyclohexanol:
In a dermal sensitisation GLP study with cyclohexanol (98.8%) in olive oil (BASF 1990), adult female Pirbright White, Dunkin Hartley HOE DHPK [SPF-LAC] BO guinea pigs were tested using the method of Magnusson and Kligman (Guinea Pig Maximization Test - GPMT) according to the OECD TG 406. Two control groups were employed in the main study, each comprising of 10 animals. 20 guinea pigs were used in the test group. At intradermal induction, injection of 5% cyclohexanol in olive-oil DAB 9 caused distinct erythema and oedema in all 20 test animals at the 24h observation time point. Necrotic skin changes in addition to distinct oedema could be observed at the injection sites of 5% cyclohexanol in Freund's adjuvant / 0.9% aqueous NaCl-solution (1:1) in all 20 test animals. The control animals injected with olive oil DAB 9 (vehicle) showed only distinct erythema. After percutaneous induction with the minimal irritating concentration (50% cyclohexanol in olive-oil DAB 9), necrotic skin changes (caused by the intradermal induction) accompanied by distinct oedema were observed in all test animals at the 48h observation time point. All animals of control group 1 and 2 which received olive oil DAB 9 (vehicle) exhibited incrustation, partially open (caused by the intradermal induction) in addition to distinct erythema and oedema. After first challenge with the maximal non-irritating concentration (25% cyclohexanol in olive-oil DAB 9) as well as with olive oil DAB 9 (vehicle), slight to distinct erythema were recorded in the controls as well as the test group after 24 hours. These skin irritation effects however, were no longer present at the 48h and 72h observation time points. A similar trend was also noticed after the second challenge where slight to distinct erythema seen after 24h in test and control animals, rechallenged with 25% cyclohexanol in olive-oil DAB 9 and olive oil DAB 9 (vehicle), were no longer present at the 48h and 72h observation time points. Hence, no animal, neither in the control groups nor in the test group showed positive reactions after the first challenge (20 days after intradermal induction) or after the rechallenge (7 days after challenge). This study is considered to be relevant, adequate, and reliable for the purposes of classification and risk assessment.
Cyclohexanone:
Bruze et al. conducted a GPMT with pure Cyclohexanone which showed negative results. A mouse ear swelling test, a guinea pig maximization test and a Buehler test (Gad et al., 1986) showed no skin sensitizing properties for Cyclohexanone.
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Classification, Labelling, and Packaging Regulation (EC) No. 1272/2008
The available experimental test data are reliable and suitable for classification purposes under Regulation 1272/2008. No sensitising properties were observed in any of the tests available. Therefore, the substance does not need require classifcation as a skin sensitizer under Regulation (EC) No. 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.